RARA and acute promyelocytic leukemia: The combination of ATRA and CDDO synergistically induced the expression of RAR-β2 partially through enhancing H3-Lys9 acetylation on the promotor region of RAR-β2 gene, thereby increasing the binding between RAR and RAREs in both ATRA-sensitive and -resistant APL cells [55].